Gynaecological disorders such as endometriosis, PCOS, and menstrual irregularities are common and often associated with pain and disruption to everyday life. They are typically diagnosed late, and many women experience both physical discomfort and mental distress for years before receiving treatment.

Now, a new register-based study from the University of Southern Denmark reveals that depression is more prevalent among women with one of the 24 most common gynaecological conditions—and that mental health symptoms often appear long before a diagnosis is made.

MIT chemists synthesized a fungal compound that holds promise for treating brain cancer. Early studies find derivatives of the compound, verticillin A, can kill certain glioma cells.

Dr. Leonard Berry, a health services researcher and professor of marketing at Texas A&M University, co-author of a recent article in JCO Oncology Practice, argues that shared decision-making (SDM) — a collaborative process where clinicians and patients make treatment choices together — should systematically include family caregivers.

Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope to ovarian cancer patients who do not respond to existing treatments. Conducted entirely at the University of Colorado Anschutz, this research has advanced from the laboratory to a Phase 1 clinical trial on the campus.

The findings, published today in Cancer Research Communications, outline a promising strategy that combines a PARP inhibitor, a targeted drug used to treat certain types of ovarian cancer, with a novel therapy, SM08502, to attack cancer from two directions. This innovative approach boosts the effectiveness of the treatment, even for patients who are no longer responding to PARP inhibitor therapy. “This achievement exemplifies true bench-to-bedside innovation entirely done at CU Anschutz,” said the paper’s first author Bradley Corr, MD, associate professor and director of clinical research in gynecologic oncology at CU Anschutz. “To the best of our knowledge, this is the first clinical trial to successfully combine these classes of drugs. While the concept has been discussed before, no one has moved it into the clinic until now. That’s what makes this approach truly novel.”